NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.17 -0.18 (-2.83 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's Range$6.11Now: $6.17▼$6.3950-Day Range$5.15MA: $6.00▼$6.8452-Week Range$3.42Now: $6.17▼$9.37Volume59,949 shsAverage Volume72,954 shsMarket Capitalization$129.68 millionP/E RatioN/ADividend YieldN/ABeta3.1 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLMD Previous Symbol CUSIPN/A CIK1595353 Webhttp://www.galmedpharma.com/ Phone972-3693-8448Debt Debt-to-Equity Ratio0.01 Current Ratio22.78 Quick Ratio22.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.04 million Price / Sales63.57 Cash FlowN/A Price / Cash FlowN/A Book Value$4.18 per share Price / Book1.48Profitability EPS (Most Recent Fiscal Year)($0.54) Net Income$-9,860,000.00 Net MarginsN/A Return on Equity-19.16% Return on Assets-18.42%Miscellaneous Employees17 Outstanding Shares21,018,000Market Cap$129.68 million Next Earnings Date3/11/2020 (Estimated) OptionableOptionable Receive GLMD News and Ratings via Email Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GLMD Rates by TradingView Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions What is Galmed Pharmaceuticals' stock symbol? Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD." How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) issued its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.11. View Galmed Pharmaceuticals' Earnings History. When is Galmed Pharmaceuticals' next earnings date? Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Galmed Pharmaceuticals. What price target have analysts set for GLMD? 6 Wall Street analysts have issued 1-year price objectives for Galmed Pharmaceuticals' stock. Their forecasts range from $10.00 to $28.00. On average, they anticipate Galmed Pharmaceuticals' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 207.9% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals. What is the consensus analysts' recommendation for Galmed Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals. Has Galmed Pharmaceuticals been receiving favorable news coverage? Media headlines about GLMD stock have trended very negative on Friday, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Galmed Pharmaceuticals. Who are some of Galmed Pharmaceuticals' key competitors? Some companies that are related to Galmed Pharmaceuticals include Milestone Pharmaceuticals (MIST), Magenta Therapeutics (MGTA), Viking Therapeutics (VKTX), CytoDyn (CYDY), Satsuma Pharmaceuticals (STSA), BioDelivery Sciences International (BDSI), Prothena (PRTA), Cue Biopharma (CUE), BioSpecifics Technologies (BSTC), Organogenesis (ORGO), Sinovac Biotech (SVA), Merus (MRUS), Beyondspring (BYSI), Innate Pharma (IPHYF) and OrganiGram (OGI). What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Rite Aid (RAD), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Immunomedics (IMMU), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), SCYNEXIS (SCYX) and Verastem (VSTM). Who are Galmed Pharmaceuticals' key executives? Galmed Pharmaceuticals' management team includes the folowing people: Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)Mr. Yohai Stenzler, CFO & Controller (Age 36)Mr. Guy Nehemya, Chief Operating Officer (Age 34)Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)Dr. Tali Gorfine, Chief Medical Officer (Age 49) Who are Galmed Pharmaceuticals' major shareholders? Galmed Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Raymond James & Associates (1.92%), Voss Capital LLC (0.72%), P.A.W. Capital Corp (0.48%), ARK Investment Management LLC (0.43%), Renaissance Technologies LLC (0.31%) and Phoenix Holdings Ltd. (0.09%). Which major investors are selling Galmed Pharmaceuticals stock? GLMD stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd.. Which major investors are buying Galmed Pharmaceuticals stock? GLMD stock was purchased by a variety of institutional investors in the last quarter, including Voss Capital LLC, Raymond James & Associates, Renaissance Technologies LLC, P.A.W. Capital Corp, ARK Investment Management LLC and Tower Research Capital LLC TRC . How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Galmed Pharmaceuticals' stock price today? One share of GLMD stock can currently be purchased for approximately $6.17. How big of a company is Galmed Pharmaceuticals? Galmed Pharmaceuticals has a market capitalization of $129.68 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.View Additional Information About Galmed Pharmaceuticals. What is Galmed Pharmaceuticals' official website? The official website for Galmed Pharmaceuticals is http://www.galmedpharma.com/. How can I contact Galmed Pharmaceuticals? Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448. MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 408 (Vote Outperform)Underperform Votes: 219 (Vote Underperform)Total Votes: 627MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: How much money do you need to begin day trading?
